Rallybio Corporation (NasdaqCM: RLYB)
Health Care · Biotechnology · US
$16.80
-1.12% today · +239.9% 1Y
Rallybio Corporation (NasdaqCM: RLYB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $90.23M and employs 9 people.
Over the last twelve months the share price has gained 239.9%, trading between 3.67 and 17.57.
Tweenvest scores Rallybio Corporation across four factors: quality 26/100, value 38/100. Its strongest factor is value.
RLYB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $90.23M
- Revenue (TTM)
- $646.00K
- P/E
- 2.13
- EPS
- 7.99
- Dividend yield
- —
- Beta (5Y)
- -0.86
- 52-week high
- $17.57
- 52-week low
- $3.67
- Avg volume (3M)
- —
- Shares outstanding
- 5.31M
- Employees
- 9
- Next earnings
- —
About Rallybio Corporation
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
- ISIN
- US75120L2097
- Founded
- 2018
- Listed since
- Jul 29, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.16 | +0.62% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $446.73 | +0.65% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.14 | +0.95% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $553.69 | +1.11% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $839.98 | +1.39% |
| argenx SEENXTBR: ARGX | $63.06B | €877.40 | +1.53% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $155.66 | +12.07% |
Figures last refreshed Aug 18, 2026.